cover
Contact Name
Eko Risdianto
Contact Email
eko_risdianto@unib.ac.id
Phone
+6285267321435
Journal Mail Official
eko_risdianto@unib.ac.id
Editorial Address
CV Media Inti Teknologi Ruko B, RT 05 RW 01 Jalan Pinang Mas, Bentiring Permai, Muara Bangkahulu, Kota Bengkulu Indonesia. 38229
Location
Kota bengkulu,
Bengkulu
INDONESIA
Journal of Natural Products and Drug Development
ISSN : -     EISSN : 31239838     DOI : https://doi.org/10.58723/jnpdd.v2i1.57
Core Subject :
The journal accepts original manuscripts, case studies, and literature reviews that cover, but are not limited to, the following topics: Natural Product Chemistry and Biology: Isolation, purification, and structural characterization of bioactive compounds from natural sources. Pharmacology and Mechanisms of Action: Pharmacological evaluation (in-vitro and in-vivo), including dose-response studies, molecular mechanisms, and pharmacodynamics. Development of Drug Formulations and Delivery Systems: Development of ready-made forms, formulations, and delivery systems of natural products-based drugs. Phytochemistry and Pharmacognosy: Qualitative and quantitative analysis, extract standardization, and phytochemical analysis methods. Network Pharmacology: A computational approach to understanding the complex interactions between natural products and biological targets. Pharmaceutical Biology and Biotechnology: Secondary metabolite production, biosynthesis, and genetic engineering to increase the production of bioactive compounds. In-silico Studies: Molecular modeling, docking, and virtual screening to identify drug candidate compounds from nature. Medical Chemistry: The design, synthesis, and structural modification of natural compounds to enhance their therapeutic potential. Bioequivalence and Biopharmaceutical Tests: Bioavailability evaluation and other biopharmaceutical studies for natural medicinal products.
Arjuna Subject : -
Articles 11 Documents
Antipyretic Activity of Ethanolic Extract of Orthosiphon aristatus Leaves in Male Mice Induced with 5% Peptone Chindiana Khutami; Elpa Giovana Zola; Suci Wulandari
Journal of Natural Products and Drug Development Vol. 2 No. 2 (2026): Journal of Natural Products and drug Development
Publisher : CV Media Inti Teknologi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58723/jnpdd.v2i2.166

Abstract

Background: Paracetamol, a first-line antipyretic, has limitations including a risk of hepatotoxicity at high doses and variations in effectiveness among products, making the exploration of natural antipyretic agents important. Orthosiphon aristatus leaves contain flavonoids, saponins, and tannins that may inhibit prostaglandin biosynthesis.Aims: This study aimed to evaluate the ability of an ethanolic extract of Orthosiphon aristatus leaves to reduce fever in male mice induced with 5% peptone.Methods: This laboratory experimental study used a completely randomized design involving 30 male white mice divided into five groups: negative control (0.5% Na-CMC), positive control (paracetamol 1.3 mg/20 g body weight), and ethanolic extract groups at doses of 100, 200, and 400 mg/kg body weight. Fever was induced by subcutaneous administration of 5% peptone. Rectal temperature was measured at baseline (Tbaseline), 1 hour after induction (T0), and at 30, 60, 90, 120, and 150 minutes after treatment (T30–T150).Data were analyzed using one-way ANOVA followed by the LSD post hoc test.Result: Phytochemical screening showed that the extract contained alkaloids, flavonoids, tannins, and saponins, with an extract yield of 11.02%. From 90 to 150 minutes, none of the three extract doses differed significantly from paracetamol (p > 0.05), whereas all differed highly significantly from the negative control (p < 0.001). The 100 mg/kg dose showed the fastest onset of action (41.07% at 30 minutes), while the 200 mg/kg dose produced the most stable effect.  Conclusion: The ethanolic extract of Orthosiphon aristatus leaves exhibited antipyretic activity comparable to paracetamol. The 100 mg/kg body weight dose was identified as the lowest effective dose, showing the fastest onset of action and efficacy comparable to higher doses during the stable phase (T90–T150).

Page 2 of 2 | Total Record : 11